Akèy › Kansè nan tete › New Jersey › Newark
Etid klinik pou Kansè nan tete nan Newark, NJ
18 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Newark (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Summit Health, Florham Park · 12 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Morristown Medical Center, Morristown · 17 mi lwen
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ap rekriteFaz 2
- Medical Oncology Hematology Associates, Newark
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), Newark
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), Livingston · 9 mi lwen
- Summit Medical Group PA, Florham Park · 12 mi lwen
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Ap rekriteFaz 1/2
- Summit Medical Group, Florham Park · 12 mi lwen
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Summit Medical Group, Florham Park · 12 mi lwen
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Ap rekriteEtid obsèvasyon
- Summit Medical Group, Florham Park · 12 mi lwen
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Summit Medical Group, Florham Park · 12 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Newark Beth Israel Medical Center, Newark
- Cooperman Barnabas Medical Center, Livingston · 9 mi lwen
- Morristown Medical Center, Morristown · 17 mi lwen
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Ap rekriteFaz 2
- GSK Investigational Site, Morristown · 17 mi lwen
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Ap rekriteFaz 3
- Morristown Medical Center, Morristown · 17 mi lwen
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Ap rekrite
- Rutgers State University of New Jersey Medical School, Newark
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Morristown Medical Center, Morristown · 17 mi lwen
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
Ap rekrite
- Summit Health, Florham Park · 12 mi lwen
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Ap rekriteFaz 2
- RWJBarnabas Health - Newark Beth Israel Medical Center, Newark
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Ap rekriteFaz 1
- RWJBarnabas Health Clara Maas Medical Center, Belleville · 4 mi lwen
- Cooperman Barnabas Medical Center, Livingston · 9 mi lwen
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Ap rekriteFaz 4
- Cancer Center Initiative, Newark
- University Hospital, Newark
- RWJBarnabas Health Newark Beth Israel Medical Center, Newark
- ak 2 plis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- Morristown Medical Center, Morristown · 17 mi lwen
Etid Kansè nan tete nan lòt vil
- New York City, NY134 etid
- Houston, TX126 etid
- Boston, MA111 etid
- Nashville, TN80 etid
- Los Angeles, CA72 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Durham, NC63 etid
- Queens, NY63 etid
- Chicago, IL58 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Newark
- Kansè Poumon ki pa ti selil14 etid
- Blesi miyèl epinyè13 etid
- Leksemi mieloïd egi12 etid
- Kansè Metastatik10 etid
- Ensifizyans kadyak10 etid
- Kansè pankreyas9 etid
- Maladi kadyovaskilè9 etid
- Melanom8 etid
- Kansè poumon7 etid
- Kansè (tout kalite)7 etid
- Maladi Crohn7 etid
- Akidan serebavaskilè6 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.